Table 2. Univariable associations of categorical demographic and clinical variables with time to reach EDSS 6.0 among multiple sclerosis (MS) patients stratified on late-onset (LOMS) or young-onset (YOMS) of disease.
| Variables | Variables | LOMS cohort (N1 = 99) | YOMS cohort (N2 = 804) | Log-rank p -value | ||
|---|---|---|---|---|---|---|
| Patients who reached EDSS 6.0, n1 = 19 (19.2%) | Category total | Patients who reached EDSS 6.0, n2 = 126 (15.7%) | Category total | |||
| Gender | 0.005 | |||||
| Female | 14 (73.7) | 71 | 70 (44.4) | 523 | ||
| Male | 5 (26.3) | 28 | 56 (55.6) | 281 | ||
| Family history | 3 (16.7) | 10 | 19 (15.1) | 124 | 0.179 | |
| Clinical presentation | ||||||
| Supratentorial | 2 (14.3) | 21 | 28 (22.2) | 201 | 0.800 | |
| Optic | 3 (15.6) | 19 | 27 (21.4) | 178 | 0.252 | |
| Brainstem/Cerebellar | 7 (36.6) | 29 | 33 (26.2) | 229 | 0.087 | |
| Spinal cord | 13 (68.4) | 46 | 49 38.9) | 260 | 0.065 | |
| Multifocal | 4 (21.1) | 12 | 9 (7.1) | 54 | 0.588 | |
| Disease Modifying Therapies | 0.977 | |||||
| Not on treatment | 1 (5.6) | 7 | 19 (17.0) | 97 | ||
| First line therapy* | 11 (61.1) | 41 | 36 (32.1) | 317 | ||
| Second line therapy** | 6 (33.3) | 39 | 57 (50.9) | 318 | ||
EDSS: Expanded Disability Status Scale
* First line therapy: Interferon Beta, Glatiramer Acetate, Teriflunomide, Dimethyl Fumarate
** Second line therapy: Fingolimod, Natalizumab, Mitoxantrone, Cyclophosphamide, Rituximab